Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains

Beer, Ronny; Engelhardt, K.; Pfausler, Bettina; Broessner, Gregor; Helbok, Raimund; Lackner, Peter; Brenneis, Christian; Kaehler, Stefan T.; Georgopoulos, Apostolos P.; Schmutzhard, Erich

doi:10.1128/aac.00515-06

Cited by 67 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although not standardized, this approach is occasionally necessary in patients with nosocomial EVD-related ventriculitis that is difficult to eradicate. Other agents have been successfully utilized in the treatment of nosocomial staphylococcal ventriculitis and meningitis, as fosfomycin [33], linezolid [3,23,28,29] and most recently daptomycin [7]. Importantly however, the latter agents should be reserved for CSF infections with mulidrugresistant gram-positive bacteria.…”

Section: Therapymentioning

confidence: 97%

See 1 more Smart Citation

Nosocomial ventriculitis and meningitis in neurocritical care patients

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Therapymentioning

confidence: 97%

“…According to our experience [3,32,33] the decision as to whether the catheter should be removed or retained largely depends on the causing organism. This view is supported by recommendations recently published in a topic-specific review on intravascular catheter-related infections [36].…”

Section: Algorithm For the Management Of Suspected Evdrelated Ventricmentioning

confidence: 98%

Nosocomial ventriculitis and meningitis in neurocritical care patients

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Linezolid, the first oxazolidinone, which is active against Gram-positive bacteria, has amphiphilic properties, possesses a V d of approximately 1 liter/kg, and readily enters the CSF with an AUC CSF /AUC S ratio close to 1 (20,252). Although primarily bacteriostatic, linezolid has been employed successfully for CNS infections caused by multiresistant organisms (211).…”

Section: Oxazolidinonesmentioning

confidence: 99%

Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

2010

View full text Add to dashboard Cite

SUMMARY The entry of anti-infectives into the central nervous system (CNS) depends on the compartment studied, molecular size, electric charge, lipophilicity, plasma protein binding, affinity to active transport systems at the blood-brain/blood-cerebrospinal fluid (CSF) barrier, and host factors such as meningeal inflammation and CSF flow. Since concentrations in microdialysates and abscesses are not frequently available for humans, this review focuses on drug CSF concentrations. The ideal compound to treat CNS infections is of small molecular size, is moderately lipophilic, has a low level of plasma protein binding, has a volume of distribution of around 1 liter/kg, and is not a strong ligand of an efflux pump at the blood-brain or blood-CSF barrier. When several equally active compounds are available, a drug which comes close to these physicochemical and pharmacokinetic properties should be preferred. Several anti-infectives (e.g., isoniazid, pyrazinamide, linezolid, metronidazole, fluconazole, and some fluoroquinolones) reach a CSF-to-serum ratio of the areas under the curves close to 1.0 and, therefore, are extremely valuable for the treatment of CNS infections. In many cases, however, pharmacokinetics have to be balanced against in vitro activity. Direct injection of drugs, which do not readily penetrate into the CNS, into the ventricular or lumbar CSF is indicated when other effective therapeutic options are unavailable.

show abstract

“…Preliminary data suggest a successful treatment of VPS infection caused by MRSE, MRSAor glycopeptide-resistant Enterococcus faecium with linezolid [109,114,115,116,117,118]. The treatment with linezolid, however, should be restricted to infections with particular multiresistant Gram-positive pathogens; due to the risk of severe neurotoxic side effects, the administration period should be limited to 21 days.…”

Section: Empirical Antimicrobial Treatmentmentioning

confidence: 99%

Epidemiology, Prevention and Management of Ventriculoperitoneal Shunt Infections in Children

Prusseit

Simon²,

Brelie³

et al. 2009

Pediatr Neurosurg

115

View full text Add to dashboard Cite

The advent of ventriculoperitoneal shunts (VPS) represented a substantial progress in the neurosurgical management of hydrocephalus in children. VPS infection is the most frequently observed complication. VPS infection is related to substantial morbidity and mortality, and exerts a negative impact on the quality of life of patients. Considerable personnel and financial resources have been devoted to its diagnosis and treatment. This article reviews the current literature and includes suggestions for the prevention, diagnosis and management of VPS infections.

show abstract

Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains

Cited by 67 publications

References 24 publications

Nosocomial ventriculitis and meningitis in neurocritical care patients

Nosocomial ventriculitis and meningitis in neurocritical care patients

Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

Epidemiology, Prevention and Management of Ventriculoperitoneal Shunt Infections in Children

Contact Info

Product

Resources

About